An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging

Trial Profile

An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Dezamizumab (Primary) ; Miridesap (Primary) ; Miridesap (Primary)
  • Indications Amyloidosis
  • Focus Diagnostic use; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Apr 2018 Planned initiation date changed from 30 Mar 2018 to 5 Apr 2018.
    • 15 Mar 2018 Planned initiation date changed from 3 Mar 2018 to 30 Mar 2018.
    • 21 Feb 2018 Planned End Date changed from 11 Dec 2018 to 18 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top